These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 2880362)

  • 1. Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Nordic Dyskinesia Study Group.
    Psychopharmacology (Berl); 1986; 90(4):423-9. PubMed ID: 2880362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effects of neuroleptics on tardive dyskinesias. A video-controlled, randomized study of chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden].
    Povlsen UJ; Noring U; Meidahl B; Korsgaard S; Waehrens J; Gerlach J
    Ugeskr Laeger; 1987 Jun; 149(25):1682-5. PubMed ID: 3299955
    [No Abstract]   [Full Text] [Related]  

  • 3. Tardive dyskinesia. Pathophysiological mechanisms and clinical trials.
    Gerlach J
    Encephale; 1988 Sep; 14 Spec No():227-32. PubMed ID: 2905651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
    Silver H; Geraisy N; Schwartz M
    J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia.
    Lublin H; Gerlach J; Hagert U; Meidahl B; Mølbjerg C; Pedersen V; Rendtorff C; Tolvanen E
    Eur Neuropsychopharmacol; 1991 Dec; 1(4):541-8. PubMed ID: 1822319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haloperidol-induced tardive dyskinesia in monkeys.
    Gunne LM; Bárány S
    Psychopharmacology (Berl); 1976 Nov; 50(3):237-40. PubMed ID: 826968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum concentrations of haloperidol pyridinium metabolites and the relationship with tardive dyskinesia and parkinsonism: a cross-section study in psychiatric patients.
    Ulrich S; Sandmann U; Genz A
    Pharmacopsychiatry; 2005 Jul; 38(4):171-7. PubMed ID: 16025420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of parkinsonism and antiparkinsonian therapy in the subsequent development of tardive dyskinesia.
    Elliott KJ; Lewis S; el-Mallakh RS; Looney SW; Caudill R; Bacani-Oropilla T
    Ann Clin Psychiatry; 1994 Sep; 6(3):197-203. PubMed ID: 7881501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients.
    Ghadirian AM; Annable L; Bélanger MC; Chouinard G
    J Clin Psychiatry; 1996 Jan; 57(1):22-8. PubMed ID: 8543543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for drug-induced parkinsonism in tardive dyskinesia patients.
    Hansen TE; Brown WL; Weigel RM; Casey DE
    J Clin Psychiatry; 1988 Apr; 49(4):139-41. PubMed ID: 2895762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine.
    Gerlach J; Simmelsgaard H
    Psychopharmacology (Berl); 1978 Oct; 59(2):105-12. PubMed ID: 103110
    [No Abstract]   [Full Text] [Related]  

  • 12. A longitudinal study of correlations among tardive dyskinesia, drug-induced parkinsonism, and psychosis.
    Hansen TE; Weigel RM; Brown WL; Hoffman WF; Casey DE
    J Neuropsychiatry Clin Neurosci; 1992; 4(1):29-35. PubMed ID: 1352714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulpiride in tardive dyskinesia.
    Gerlach J; Casey DE
    Acta Psychiatr Scand Suppl; 1984; 311():93-102. PubMed ID: 6142590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study.
    Chouinard G
    J Clin Psychopharmacol; 1995 Feb; 15(1 Suppl 1):36S-44S. PubMed ID: 7537286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a cholinomimetic drug (RS 86) in tardive dyskinesia and drug-related parkinsonism.
    Noring U; Povlsen UJ; Casey DE; Gerlach J
    Psychopharmacology (Berl); 1984; 84(4):569-71. PubMed ID: 6152058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
    Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
    J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate.
    Hyde TM; Egan MF; Wing LL; Wyatt RJ; Weinberger DR; Kleinman JE
    Psychopharmacology (Berl); 1995 Mar; 118(2):142-9. PubMed ID: 7617800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Side effects in preventive maintenance therapy with neuroleptics with special emphasis on tardive dyskinesia.
    Logothetis J; Paraschos A; Frangos E
    Bibl Psychiatr; 1981; (160):22-9. PubMed ID: 6109528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coexistent tardive dyskinesia and parkinsonism.
    Jankovic J; Casabona J
    Clin Neuropharmacol; 1987 Dec; 10(6):511-21. PubMed ID: 2892586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluperlapine in tardive dyskinesia and parkinsonism.
    Korsgaard S; Noring U; Gerlach J
    Psychopharmacology (Berl); 1984; 84(1):76-9. PubMed ID: 6149595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.